Management of Tetralogy of Falot - case presentation of a School going child presenting with central and peripheral Cyanosis, finger nail clubbing Grade IV with a history easy fatiguability and occasional Tet spells since the age of 2.
A detailed discussion on embryogenesis of heart and ennumeration of all congenital diseases and description of cyanotic congenital heart disease , each disease in detail.
TAPVC defines the anomaly in which the pulmonary veins have no connection with the left atrium. Rather, the pulmonary veins connect directly to one of the systemic veins (TAPVC) or drain in to right atrium.
A PFO or ASD is present essentially in those who survive after birth
When pulmonary veins drain anomalously into the right atrium either because of complete absence of the interatrial septum or malattachment of the septum primum , then it is known as total anomalous pulmonary venous drainage.
When some or all of the pulmonary veins drain anomalously in to RA or its tributaries without being abnormally connected, the terms partially anomalous pulmonary venous drainage (PAPVD) or totally anomalous pulmonary venous drainage (TAPVD) with normal pulmonary venous connections are used.
A detailed discussion on embryogenesis of heart and ennumeration of all congenital diseases and description of cyanotic congenital heart disease , each disease in detail.
TAPVC defines the anomaly in which the pulmonary veins have no connection with the left atrium. Rather, the pulmonary veins connect directly to one of the systemic veins (TAPVC) or drain in to right atrium.
A PFO or ASD is present essentially in those who survive after birth
When pulmonary veins drain anomalously into the right atrium either because of complete absence of the interatrial septum or malattachment of the septum primum , then it is known as total anomalous pulmonary venous drainage.
When some or all of the pulmonary veins drain anomalously in to RA or its tributaries without being abnormally connected, the terms partially anomalous pulmonary venous drainage (PAPVD) or totally anomalous pulmonary venous drainage (TAPVD) with normal pulmonary venous connections are used.
This file was made while my course of studying pediatrics at college,intednded to make the cardiology lessons more organized and easier to study and memorize. And I do hope it will be useful to the other medical students who read it.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
4. 4 THINGS
Subvalvar pulmonary stenosis with ? Hypoplasia
of PA- valve and arteries
Non restrictive VSD
RVH
Overriding Aorta
Neonates: Pulmonary blood flow maintained by
PDA and MAPCA ( from ascending and
descending arteries)
5.
6. C/P
Central cyanosis usually in the first year of life.
Cyanosis dependant on stenosis.
Squatting - ↑SVR → ↑ aortic pressure and
hence ↑pulmonary blood flow.
Grey Sclerae and Engorged Blood vessels
during tet spells.
Clubbing
Hypoxic “tet” spells: due to infudibular spams.
Occur in te morning, after crying, feeding and
exercabated by stress.
7. TET SPELLS
Hyperapnea, restless
Cyanosis
Reduced mummer
Followed by generalised weakness and sleep.
Severe ones can lead to LOC, CONVULSIONS,
HEMIPARESIS
NOTE: Infants without cyanosis and have TOF
cyanosis suffer the most spells.
8. COMPLICATIONS OF TOF
Cerebral Thrombosis: Causing CVA
- long standing hypoxemia causing ↑EPO →
polycythemia →sluggish flow.
- Fe deficiency anaemia ( due to ↑EPO,
Phlebotomy) disinhibits megakaryocytes.
o Brain Abscess: Due to septic emboli and lack of
pulmonary filtration. Presents as low grade fever
with behavioural changes, Headaches,
seizures, focal neurologic deficits.
9. Bacterial Endocarditis
Pulmonary TB
Reduced School perfomance
FTT
NO HEART FAILURE
Associated with: DiGeorge Syndrome (22q11.2
deletion) and CATCH 22( Cardiac, Abnormal
facies, cleft palate, hypocalcemia and 22 deletion)
10. GENERAL PRINCIPLES OF CHD MX
Parents Counselling
Modify Physical activity appropriate for age
(don’t restrict totally but avoid high impact
sports)
Routine immunization and prophylaxis against
bacterial infections(dental surgery) and
RSV/Influenza.
Anticipate complications and look for them.
Avoid dehydration and you avoid stroke-viscosity
Phlebotomy indicated in very symptomatic pts or
HCT>65
11. INVESTIGATIONS
1. Hyperoxic Test, O2 sats
2. FBC – Hb 19.8 ( 23.2 in 2014) - HCT 69.1 ( 73.1 in
2014)
3. Coagulation Profile
4. ABG – Sr lactates, base excess, PaO2
5. Blood cultures in febrile patients.
6. Knee arthrocentesis for knee swelling
7. ESR, CRP and ASOT
8. ANA, RF
12. IMAGING
CXR – boot shaped heart with oligeamic lungs.
ECG – RBBB with RAD and RVH (2014)
ECHO – Infundibular stenosis, Overriding Aorta,
Normal AV valves, Hypertrophic infundibular
septum (2014)
Cardiac catheterization: assesses pressure in Rt
ventricles and pulmonary artery, and anatomy.
MRI – GOLD STANDARD
X RAY joint
Others: Chromosomal studies at birth.
14. TX OF HYPERCYANOTIC SPELLS
Knee chest position
Avoid Iatrogenic stressors
Remove constrictive clothes
Adminster O2 (of limited value until propranolol)
Sodium bicarbonate to correct acidosis
Propranolol 0.1mg/kg
Morphine 0.1mg/kg SC or midazolam IV
0.1mg/kg or ketamne 1-2mg/kg IV
If still not responsive, admit to PICU, intubate
and sedate. This usually does the job.
Monitor O2 sats and other vitals
15. SUBSEQUENT TX AFTER SPELL
Oral prophyaxis propranolol 2-6mg/kg/d
Avoid digitalis as it may induce infundibular
spasms.
Vasodilator drugs can be used too such as
sildenafil.
Phlebotomy with replacement of normal saline is
a long time therapeutic modality
16. THERAPEUTIC PHLEBOTOMY ( OTHER
INDICATIONS)
Polycythermia vera
Hemochromatosis
Porphyria cutanea tarda
NAFLD with hyperferritinemia
ADVERSE EFFECTS
o Post phlebotomy thrombosis
o Hematoma at site of injection
o syncope
17. AVOID CEREBRAL THROMBOSIS
Tx of Fe deficiency Anemia
Avoid dehydration
Partial exchange transfusion with albumen or
normal saline if HCT>65
PGE2 infusion at birth if severe cyanosis
Look out for and treat Infective endocarditis.
18. SURGERY – PALLIATIVE SHUNTS
Idea: anastomosis btwn aorta and PA to
↑pulmonary blood flow
Indication: cyanotic infants < 3mo
TYPES
- Modified Blalock Taussig: anastomosis btwn
subclavian artery and ipsilateral PA.
- Waterstone operation: Ascending Aorta and Rt
PA
- Potts operation: descending Aorta and Lt PA
19.
20. CORRECTIVE SURGERY
Timing : 4 to 12 months
Involves enlargement of RVOT and VSD closure.
Done by using cardiopulmonary bypass with
cardioplegia.
Replacement of valves
Postop monitoring for complications.
Patient education that repair is not curing.
21.
22. PROGNOSIS
Historically, untreated TOF average life
expectancy is 12 years.
Survival rates after Repair
– 1 month = 100 percent
- 1 year = 89 percent
- 5 years = 95 percent
23. RARELY REPORTED
COMPLICATIONS
Pépé Mfutu Ekulu, Orly Kazadi-wa-Kazadi, Paul
Kabuyi Lumbala, and Michel Ntetani Aloni,
“Nephrotic Syndrome in a Child Suffering from
Tetralogy of Fallot: A Rare Association,” Case
Reports in Pediatrics, vol. 2015, Article ID
128409, 3 pages, 2015.
24. Ischemic Retinopathy and Uveitis in a
Patient with Tetralogy of Fallot Wu, Wei-Chi
et al.Ophthalmology , Volume 112 , Issue 11 ,
1936 - 1940
25.
26. I Choi, S & V Simone, J & W Jackson, C. (1974). Megakaryocytopoiesis in
experimental iron deficiency anemia. Blood. 43. 1